RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Maravai LifeSciences Holdings Stock

Maravai LifeSciences Holdings Equity 2024

Maravai LifeSciences Holdings Equity

416.75 M USD

Ticker

MRVI

ISIN

US56600D1072

WKN

A2QHK8

In 2024, Maravai LifeSciences Holdings's equity was 416.75 M USD, a -23.56% increase from the 545.2 M USD equity in the previous year.

Maravai LifeSciences Holdings Aktienanalyse

What does Maravai LifeSciences Holdings do?

Maravai LifeSciences Holdings is a publicly traded company that was founded in 2014 and is headquartered in San Diego, California. The company operates in the biotechnology industry and specializes in the development and marketing of solutions for the life sciences. Maravai LifeSciences' business model is based on a wide portfolio of products and services, which are divided into various divisions: Nucleic Acid Production & Services, Bio-manufacturing, Bioprocessing, and Nucleic Acid Therapeutics. The Nucleic Acid Production & Services division of Maravai LifeSciences produces synthetic DNA and RNA oligonucleotides that are widely used in biomedical research. These products are utilized by numerous customers worldwide, including researchers, pharmaceutical companies, and diagnostic laboratories. The company also offers a variety of services related to nucleic acid synthesis and oligonucleotide manufacturing. In the Bio-manufacturing division, Maravai LifeSciences provides specifically designed antibodies and proteins that are used in biomedical research and diagnostics. The company also produces specialized reagents and accessories for the scientific community. The Bioprocessing division of Maravai LifeSciences offers solutions for the production of biopharmaceuticals. Here, the company develops technical expertise and manufacturing systems specialized in cellular processes. The goal is to support customers in biopharmaceutical production with more efficient and cost-effective drug manufacturing solutions. The Nucleic Acid Therapeutics division of Maravai LifeSciences develops therapeutic solutions based on DNA and RNA technology. The products are used in cancer research and treatment, as well as gene therapy. The company is dedicated to researching and developing new technologies and products to maintain a leading position in this field. Maravai LifeSciences has earned a reputation in the industry by offering innovative solutions, products, and services. The company works closely with its customers to understand their specific needs and provide tailored solutions. There is a strong commitment to research and development of new technologies and products that will meet the demand arising from the rapid development of the biotechnology industry. Overall, Maravai LifeSciences is a leading company in the development and marketing of solutions for the life sciences. With its wide portfolio of products and services and a strong commitment to research and development, the company is well-equipped to further expand its position in the industry and support its customers worldwide. Maravai LifeSciences Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Maravai LifeSciences Holdings's Equity

Maravai LifeSciences Holdings's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Maravai LifeSciences Holdings's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Maravai LifeSciences Holdings's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Maravai LifeSciences Holdings's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Maravai LifeSciences Holdings’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Maravai LifeSciences Holdings stock

What is the equity of Maravai LifeSciences Holdings this year?

Maravai LifeSciences Holdings has equity of 416.75 M USD this year.

What was the equity of Maravai LifeSciences Holdings compared to the previous year?

The equity of Maravai LifeSciences Holdings has increased/decreased by -23.56% decreased compared to the previous year.

What impact does a high equity have on investors of Maravai LifeSciences Holdings?

A high equity is advantageous for investors of Maravai LifeSciences Holdings as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Maravai LifeSciences Holdings?

A low equity can be a risk for investors of Maravai LifeSciences Holdings, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Maravai LifeSciences Holdings affect the company?

An increase in equity of Maravai LifeSciences Holdings can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Maravai LifeSciences Holdings affect the company?

A reduction in equity of Maravai LifeSciences Holdings can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Maravai LifeSciences Holdings?

Some factors that can affect the equity of Maravai LifeSciences Holdings include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Maravai LifeSciences Holdings so important for investors?

The equity of Maravai LifeSciences Holdings is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Maravai LifeSciences Holdings take to change the equity?

To change equity, Maravai LifeSciences Holdings can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Maravai LifeSciences Holdings pay?

Over the past 12 months, Maravai LifeSciences Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Maravai LifeSciences Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Maravai LifeSciences Holdings?

The current dividend yield of Maravai LifeSciences Holdings is .

When does Maravai LifeSciences Holdings pay dividends?

Maravai LifeSciences Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Maravai LifeSciences Holdings?

Maravai LifeSciences Holdings paid dividends every year for the past 0 years.

What is the dividend of Maravai LifeSciences Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Maravai LifeSciences Holdings located?

Maravai LifeSciences Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Maravai LifeSciences Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Maravai LifeSciences Holdings from 9/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did Maravai LifeSciences Holdings pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of Maravai LifeSciences Holdings in the year 2023?

In the year 2023, Maravai LifeSciences Holdings distributed 0 USD as dividends.

In which currency does Maravai LifeSciences Holdings pay out the dividend?

The dividends of Maravai LifeSciences Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Maravai LifeSciences Holdings

Our stock analysis for Maravai LifeSciences Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Maravai LifeSciences Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.